Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: The FinnDiane study

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2374-2382

  Tolonen, Nina ^a,b   Forsblom, Carol ^a,b   Mäkinen, Ville Petteri ^a,b,c,d   Harjutsalo, Valma ^a,b,e   Gordin, Daniel ^a,b   Feodoroff, Maija ^a,b   Sandholm, Niina ^a,b,f   Thorn, Lena M ^a,b   Wadén, Johan ^a,b   Taskinen, Marja Riitta ^b   Groop, Per Henrik ^a,b,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f AALTO UNIVERSITY   (Finland)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; LIPID; LIPOPROTEIN;

ADULT; ALBUMINURIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; FEMALE; FOLLOW UP; GENDER; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PREDICTION; RISK ASSESSMENT; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; GLUCOSE BLOOD LEVEL; INCIDENCE; METABOLISM; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INCIDENCE; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PROGNOSIS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84904975684     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2873     Document Type: Article

References (40)

1. Lozano R, Naghavi M, Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet 2013; 381: 628]. Lancet 2012; 380: 2095-2128
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
3. Soedamah-Muthu S.S., Fuller JH, Mulnier H.E., Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006; 29: 798-804
4. Groop PH, Thomas MC, Moran J.L., et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts allcause mortality in type 1 diabetes. Diabetes 2009; 58: 1651-1658
5. Orchard TJ, Secrest AM, Miller R.G., Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010; 53: 2312-2319
6. Mattock MB, Cronin N, Cavallo-Perin P, et al.; EURODIAB IDDM Complications Study. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 2001; 18: 59-67
7. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987; 30: 144-148
8. Stamler J, Wentworth D, Neaton JD Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-2828
9. American Diabetes Association. Standards of medical care in diabetesd2013. Diabetes Care 2013; 36(Suppl. 1): S11-S66
10. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992; 41(Suppl. 2): 12-17
11. Tolonen N, Forsblom C, Thorn L., et al.; FinnDiane Study Group. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia 2008; 51: 12-20
12. Tolonen N, Hietala K, Forsblom C., et al.; FinnDiane Study Group. Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the FinnDiane Study. J Intern Med 2013; 274: 469-479
13. Levey AS, Stevens LA, Schmid C.H., et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
14. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistancein type 1diabetes? Diabetes 2000; 49: 626-632
15. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
16. Thygesen K, Alpert JS, Jaffe A.S., et al.; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: 1581-1598
17. Sundström J., Byberg L, Gedeborg R., Michaëlsson K, Berglund L. Useful tests of usefulness of new risk factors: tools for assessing reclassification and discrimination. Scand J Public Health 2011; 39: 439-441
18. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104: 1863-1867
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
20. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
21. Orchard TJ, Olson JC, Erbey J.R., et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003; 26: 1374-1379
22. Soedamah-Muthu S.S., Chaturvedi N, Toeller M., et al.; EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 2004; 27: 530-537
23. Sniderman AD, Pedersen T, Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol 1997; 79: 64-67
24. Durrington PN, Bolton CH, Hartog M. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 1978; 82: 151-160
25. Chaturvedi N, Fuller JH, Taskinen MR; EURODIAB PCS Group. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001; 24: 2071-2077
26. Kahri J, Groop PH, Viberti G, Elliott T., Taskinen MR. Regulation of apolipoprotein A-I-containing lipoproteins in IDDM. Diabetes 1993; 42: 1281-1288
27. Cleland SJ, Fisher BM, Colhoun H.M., Sattar N., Petrie JR. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? Diabetologia 2013; 56: 1462-1470
28. Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of highdensity lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012; 4: 251-268
29. Nobecourt E, Davies MJ, Brown B.E., et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 2007; 50: 643-653
30. Ferretti G, Bacchetti T, Busni D., Rabini RA, Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against eryth-rocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004; 89: 2957-2962
31. Perségol L., Foissac M, Lagrost L., et al. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007; 50: 2384-2387
32. Zhou H, Tan KC, Shiu S.W., Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 927-933
33. Liu D, Ji L, Zhang D., et al. Nonenzymatic glycation of high-density lipoprotein impairs its anti-inflammatory effects in innate immunity. Diabetes Metab Res Rev 2012; 28: 186-195
34. Rydén L., Grant PJ, Anker S.D., et al.; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087
35. Boekholdt SM, Arsenault BJ, Mora S, et al Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302-1309
36. Thorn LM, Forsblom C, Fagerudd J., et al.; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-2024
37. McLaughlin T, Abbasi F, Cheal K., Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139: 802-809
38. Hokanson JE, Austin MA Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219
39. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066-1069
40. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903